{"analyses":[{"groupDescription":"PSA Response Enzalutamide Vs. Bicalutamide.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalMethod":"Wilcoxon rank sum test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-100.0","upperLimit":"287.7","value":"-89.03"},{"groupId":"OG001","lowerLimit":"-98.5","upperLimit":"25700.0","value":"0.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"description":"The PSA response by Week 13 was defined as the percentage change from Baseline to the smallest PSA value after Baseline (i.e., a decrease of 100% represents the largest possible decrease to a value below the lower limit of quantification) and on or before day 99 (i.e., upper boundary of the Week 13 visit window). For participants with no decrease in PSA post-baseline by Week 13, the PSA response by Week 13 was the smallest increase in PSA up to day 99. For participants with no post-baseline PSA values up to day 99, the PSA response by Week 13 was set to missing. PSA was analyzed at a central laboratory.","dispersionType":"Full Range","groups":[{"description":"Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"OG000","title":"Enzalutamide"},{"description":"Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"OG001","title":"Bicalutamide"}],"paramType":"MEDIAN","populationDescription":"Full analysis set with available PSA data","reportingStatus":"POSTED","timeFrame":"Baseline to Week 13","title":"Prostate-specific Antigen (PSA) Response by Week 13","type":"SECONDARY","unitOfMeasure":"percent change"}